Sagimet Biosciences Inc.
SGMT
Rank in Stocks
#13966
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The companyโs lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Share Price
$10.83
Last synced: 2026-11-09
Market Cap
$352.86M
Change (1 day)
9.95%
Change (1 year)
27.41%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Sagimet Biosciences Inc. (SGMT)
Category
Healthcare
EPS for Sagimet Biosciences Inc. (SGMT)
EPS as of June 2026 TTM: $-1.28
According to Sagimet Biosciences Inc.'s latest financial reports, its current EPS (TTM) is $-1.28. At the end of 2025 the company had an EPS of $-1.58, a decrease compared to its 2024 EPS of $-1.45.
EPS history for Sagimet Biosciences Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.28 | -18.99% |
| 2025 | $-1.58 | 8.97% |
| 2024 | $-1.45 | -5.23% |
| 2023 | $-1.53 | 10.87% |
| 2022 | $-1.38 | 25.45% |
| 2021 | $-1.10 | 115.69% |
| 2020 | $-0.51 | -20.31% |
| 2019 | $-0.64 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,323.44% |
US
|
|
| $-7.07 | 452.34% |
US
|
|
| $-5.29 | 313.28% |
AU
|
|
| $12.88 | -1,106.26% |
BE
|
|
| $21.56 | -1,784.38% |
NL
|
Questions about Sagimet Biosciences Inc.'s earnings per share (EPS)
What is Sagimet Biosciences Inc.'s earnings per share (EPS)?
Sagimet Biosciences Inc.'s earnings per share (EPS) over the last twelve months is $-1.28, as of Jun 2026.
What was Sagimet Biosciences Inc.'s earnings per share (EPS) in 2025?
In 2025, Sagimet Biosciences Inc.'s earnings per share (EPS) was $-1.58, compared with $-1.45 in 2024.
How has Sagimet Biosciences Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Sagimet Biosciences Inc.'s earnings per share (EPS) was highest in 2020 ($-0.51) and lowest in 2025 ($-1.58).
How does Sagimet Biosciences Inc.'s earnings per share (EPS) compare with similar companies?
Sagimet Biosciences Inc.'s earnings per share (EPS) ($-1.28) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.